Fmr LLC Acquires 6,771 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Fmr LLC increased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 220.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,841 shares of the company’s stock after acquiring an additional 6,771 shares during the period. Fmr LLC’s holdings in Pediatrix Medical Group were worth $114,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MD. Quest Partners LLC boosted its position in Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares during the period. The Manufacturers Life Insurance Company grew its stake in Pediatrix Medical Group by 3.5% in the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after purchasing an additional 1,088 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Pediatrix Medical Group by 0.5% in the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock worth $3,196,000 after buying an additional 2,083 shares during the period. Finally, Atria Investments Inc grew its position in shares of Pediatrix Medical Group by 9.0% during the 3rd quarter. Atria Investments Inc now owns 27,124 shares of the company’s stock worth $314,000 after buying an additional 2,238 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on MD. Mizuho lifted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Jefferies Financial Group increased their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Macquarie began coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Truist Financial upped their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and an average price target of $16.42.

Insider Activity

In other news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Stock Down 1.1 %

Pediatrix Medical Group stock opened at $14.09 on Monday. The business has a fifty day moving average price of $14.19 and a 200-day moving average price of $10.99. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $16.41. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.60, a PEG ratio of 2.00 and a beta of 1.57. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.29 earnings per share. Equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.